A Toxic Friend: Genotoxic and Mutagenic Activity of the Probiotic Strain Escherichia coli Nissle 1917.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
25 08 2021
Historique:
pubmed: 12 8 2021
medline: 13 1 2022
entrez: 11 8 2021
Statut: ppublish

Résumé

The probiotic Escherichia coli strain Nissle 1917 (DSM 6601, Mutaflor), generally considered beneficial and safe, has been used for a century to treat various intestinal diseases. However, Nissle 1917 hosts in its genome the

Identifiants

pubmed: 34378987
doi: 10.1128/mSphere.00624-21
pmc: PMC8386472
doi:

Substances chimiques

Escherichia coli Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0062421

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Nat Cancer. 2020 Jul;1(7):723-734
pubmed: 33768208
J Infect Dis. 2014 Jul 15;210(2):285-94
pubmed: 24489107
Nature. 2020 Apr;580(7802):269-273
pubmed: 32106218
Med Monatsschr. 1959 Aug;13:489-91
pubmed: 14427355
Environ Mol Mutagen. 2005 Aug;46(2):104-15
pubmed: 15887215
Trends Microbiol. 2020 Nov;28(11):874-876
pubmed: 32507544
mBio. 2018 Mar 20;9(2):
pubmed: 29559578
Arch Toxicol. 2020 Jun;94(6):1787-1877
pubmed: 32542409
J Clin Invest. 2014 Aug;124(8):3391-406
pubmed: 24960158
mBio. 2020 Jul 7;11(4):
pubmed: 32636253
Biol Neonate. 1997;71(4):224-32
pubmed: 9129791
Gastroenterology. 2020 Oct;159(4):1612-1614.e5
pubmed: 32603656
Genes Dev. 2018 May 1;32(9-10):620-638
pubmed: 29802124
Gut Microbes. 2012 Nov-Dec;3(6):501-9
pubmed: 22895085
Science. 2019 Feb 15;363(6428):
pubmed: 30765538
J Cell Sci. 2009 Nov 15;122(Pt 22):4070-80
pubmed: 19843584
Nat Chem. 2015 May;7(5):411-7
pubmed: 25901819
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11537-42
pubmed: 20534522
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Appl Microbiol Biotechnol. 2016 Oct;100(20):8693-9
pubmed: 27640192
Gut. 2014 Dec;63(12):1932-42
pubmed: 24658599
Nat Biotechnol. 2018 Oct;36(9):857-864
pubmed: 30102294
FEMS Microbiol Lett. 2007 Oct;275(2):255-62
pubmed: 17714479
Infect Immun. 2015 Sep;83(9):3704-11
pubmed: 26150540
mBio. 2019 Oct 1;10(5):
pubmed: 31575772
Nat Commun. 2017 Apr 11;8:15028
pubmed: 28398304
Nat Commun. 2021 Feb 12;12(1):1003
pubmed: 33579932
World J Gastroenterol. 2016 Jun 28;22(24):5505-11
pubmed: 27350728
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
PLoS Pathog. 2019 Sep 23;15(9):e1008029
pubmed: 31545853
J Exp Med. 2019 Oct 7;216(10):2378-2393
pubmed: 31358565
Nat Commun. 2020 Apr 8;11(1):1738
pubmed: 32269218
J Am Chem Soc. 2013 Mar 6;135(9):3359-62
pubmed: 23406518
Environ Mol Mutagen. 1999;33(2):167-72
pubmed: 10217071
Nature. 2016 Dec 8;540(7632):280-283
pubmed: 27798599
ACS Infect Dis. 2018 Jan 12;4(1):39-45
pubmed: 28918634
mSphere. 2020 Dec 16;5(6):
pubmed: 33328353
J Clin Gastroenterol. 2011 Nov;45 Suppl:S168-71
pubmed: 21992958
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
Gut. 2004 Nov;53(11):1617-23
pubmed: 15479682
Nat Commun. 2014 Sep 03;5:4724
pubmed: 25182170
Environ Mol Mutagen. 2017 Jun;58(5):235-263
pubmed: 28485537
Nat Med. 2020 Jul;26(7):1063-1069
pubmed: 32483361
Eur J Microbiol Immunol (Bp). 2020 Mar 17;10(1):11-19
pubmed: 32363034
Nat Commun. 2017 Nov 3;8(1):1314
pubmed: 29101366
Science. 2012 Oct 5;338(6103):120-3
pubmed: 22903521
Science. 2006 Aug 11;313(5788):848-51
pubmed: 16902142
Cell Res. 2015 Jan;25(1):9-23
pubmed: 25403473
PLoS Pathog. 2013;9(7):e1003437
pubmed: 23853582
Pediatr Infect Dis J. 2008 Jun;27(6):494-9
pubmed: 18469732
Mutat Res. 2004 Oct 4;554(1-2):375-85
pubmed: 15450433

Auteurs

Jean-Philippe Nougayrède (JP)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Camille V Chagneau (CV)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Jean-Paul Motta (JP)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Nadège Bossuet-Greif (N)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Marcy Belloy (M)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Frédéric Taieb (F)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.

Jean-Jacques Gratadoux (JJ)

Micalis, INRAE, Jouy-en-Josas, France.

Muriel Thomas (M)

Micalis, INRAE, Jouy-en-Josas, France.

Philippe Langella (P)

Micalis, INRAE, Jouy-en-Josas, France.

Eric Oswald (E)

IRSD, INSERM, INRAE, Université de Toulouse, ENVT, Toulouse, France.
CHU Toulouse, Hôpital Purpan, Service de Bactériologie-Hygiène, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH